Aakaar
enhancing life through technology
CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

13.02.2026

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AAKAAR

Dear Sir/ Madam,

Sub.: Press Release

Please find enclosed herewith a copy of a Press Release titled '**USFDA Approval of Saypha® and Marketing Advantage in India'** which will be disseminated shortly. The Press Release is self-explanatory.

The above information is also being made available on the website of the Company at https://aakaarmedical.in/disclosures-as-per-regulation-46-of-the-sebi-lodr-regulations/

Thanking you,

Yours truly,
For Aakaar Medical Technologies Ltd.

VISHWANATHAN ANOOPKUMAR PILLAI
Digitally signed by VISHWANATHAN ANOOPKUMAR PILLAI
Date: 2026.02.13 12:14:14 +05'30'

Anoopkumar V. Pillai
Company Secretary & Compliance Officer

Encl: as above.

Aakaar
enhancing life through technology
CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

USFDA Approval of Saypha® and Marketing Advantage in India

Aakaar Medical Technologies Ltd's dermal filler portfolio is strengthened by USFDA approval of Saypha (manufactured by Croma-Pharma, Austria). This approval places Saypha in the same global regulatory league as leading international brands such as Juvederm and Restylane, significantly enhancing clinician confidence and market credibility in India.

The global dermal fillers market is estimated at USD 8–9 billion (2024) and is projected to reach ~USD 14 billion by 2033, growing at ~10–11% CAGR. The India dermal fillers market is expected to grow at ~12–15% CAGR, driven by rising adoption of minimally invasive aesthetic procedures. Hyaluronic acid fillers account for the largest market share, owing to their safety, reversibility, and regulatory acceptance.

In a market where several competing fillers lack USFDA approval, Saypha's regulatory status provides Aakaar with a clear marketing and positioning advantage, supporting premium perception, faster clinician adoption, and stronger share capture in India's rapidly expanding medical aesthetics market.

For Aakaar Medical Technologies Ltd.

Rahul Babasaheb Sawakhande

Digitally signed by Rahul Babasaheb Sawakhande
Date: 2026.02.13 12:13:07 +05'30'

Dr. Rahul B. Sawakhande
CEO & Director
Mumbai,
13.02.2026